share_log

Humacyte To Present Phase 3 Results Comparing Efficacy And Safety Of Tissue-Engineered Vessel To AV Fistulas In End-Stage Renal Disease Patients At VEITH Symposium On November 23, 2024

Humacyte To Present Phase 3 Results Comparing Efficacy And Safety Of Tissue-Engineered Vessel To AV Fistulas In End-Stage Renal Disease Patients At VEITH Symposium On November 23, 2024

Humacyte将在2024年11月23日的VEITH研讨会上展示对比组织工程血管与动静脉瘘在终末期肾病患者中疗效和安全性的第三阶段结果。
Benzinga ·  2024/11/22 21:02

Humacyte To Present Phase 3 Results Comparing Efficacy And Safety Of Tissue-Engineered Vessel To AV Fistulas In End-Stage Renal Disease Patients At VEITH Symposium On November 23, 2024

Humacyte将在2024年11月23日的VEITH研讨会上展示对比组织工程血管与动静脉瘘在终末期肾病患者中疗效和安全性的第三阶段结果。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发